College of Veterinary Medicine to conduct testing

Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: “HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory.

The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project.  The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.

Dr. Russell Carr in the College of Veterinary Medicine stated, “My colleagues and I at the University are excited about the potential that the outcomes will have and the opportunity to collaborate with the Halberd Corporation.”

Details on scope and timing to follow

To get the latest news on Halberd’s exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States.  The College’s main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center.  The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians.  MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.

About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time the statements are made.  These statements may address issues that involve significant risks, uncertainties and associated estimates made by management.  Actual results could differ materially from current projections or implied results.  Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.